Protective effect of florfenicol on acute lung injury induced by lipopolysaccharide in mice

Zhang, Xuemei; Song, Keji; Xiong, Huanzhang; Li, Hongyu; Chu, Xiao; Deng, Xuming

doi:10.1016/j.intimp.2009.09.007

Cited by 86 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, the drug had a little effect on IL-1β and IL-10 secretion. Further studies conducted in vivo on mice challenged with LPS also showed that florfenicol significantly attenuated TNF and IL-6 production in the murine serum (Zhang et al 2009). The studies carried out in vitro showed that florfenicol modulated early cytokine response by blocking the NF-kappaB pathway in RAW 264.7 macrophages (Zhang et al 2008).…”

Section: Discussionmentioning

confidence: 97%

The effects of florfenicol on lymphocyte subsets and humoral immune response in mice

Lis¹,

Szczypka²,

Suszko³

et al. 2011

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

The effects of florfenicol on lymphocyte subsets and humoral immune response in mice

Lis¹,

Szczypka²,

Suszko³

et al. 2011

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…ALI was induced with LPS, as previously described (Zhang et al, 2009). Briefly, mice were challenged with 10 mg of LPS in 50 ml PBS intranasally (i.n.)…”

Section: Murine Model Of Lps-induced Alimentioning

confidence: 99%

Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice

Shi

Zheng

Wang

et al. 2014

Pharmaceutical Biology

View full text Add to dashboard Cite

Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice, Pharmaceutical Biology, 52:6, 729-734, DOI: 10.3109/13880209.2013 Materials and methods:Female BALB/c mice were treated with commercial mogroside V (2.5, 5 and 10 mg/kg) for 1 h prior to intranasal injection of LPS (10 mg in 50 ml). After 12 h, airway inflammation in the ALI model was determined by the wet/dry weight (W/D) ratio, myeloperoxidase (MPO) activity of lung tissue, leukocyte recruitment and cytokine levels in the bronchoalveolar lavage fluid (BALF). Additionally, lung tissue was examined by histology and western blotting to investigate the changes in pathology and the signalling in the presence and absence of mogroside V. Results: Mogroside V at 5 and 10 mg/kg inhibited airway inflammation induced by LPS as measured by the decrease in the histological changes (44 and 67.3% reduction in lung injury score, respectively), a 28.9 and 55.3% reduction in lung MPO activity, and inflammatory cell counts, interleukin-1b (IL-1b, 382 and 280 pg/ml, respectively), IL-6 (378 and 232 pg/ml, respectively) and tumor necrosis factor-a (TNF-a, 12.5 and 7.8 ng/ml, respectively) levels in the BALF. Additionally, mogroside V treatment reduced the activation of cyclooxygenase 2 (COX-2), inducible NO synthase (iNOS), and the nuclear factor (NF)-kB. Discussions and conclusions: Together, these data suggest that mogroside V has the potential to protect against LPS-induced airway inflammation in a model of ALI.

show abstract

“…sepsis, pancreatitis, burns, gynecological conditions (amniotic fluid embolism, eclampsia, placental abruption) and massive blood transfusion. The clinical incidence of ALI/ARDS is high and the condition is associated with marked mortality and morbidity (2,3).…”

Section: Introductionmentioning

confidence: 99%

Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity

Zhu

Guo

Huang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Acute lung injury (ALI) is characterized by excessive inflammatory responses and oxidative injury in the lung tissue. It has been suggested that anti-inflammatory or antioxidative agents could have therapeutic effects in ALI, and eriodictyol has been reported to exhibit antioxidative and anti-inflammatory activity in vitro. The aim of the present study was to investigate the effect of eriodictyol on lipopolysaccharide (LPS)-induced ALI in a mouse model. The mice were divided into four groups: Phosphate-buffered saline-treated healthy control, LPS-induced ALI, vehicle-treated ALI (LPS + vehicle) and eriodictyol-treated ALI (LPS + eriodictyol). Eriodictyol (30 mg/kg) was administered orally once, 2 days before the induction of ALI. The data showed that eriodictyol pretreatment attenuated LPS-induced ALI through its antioxidative and anti-inflammatory activity. Furthermore, the eriodictyol pretreatment activated the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway in the ALI mouse model, which attenuated the oxidative injury and inhibited the inflammatory cytokine expression in macrophages. In combination, the results of the present study demonstrated that eriodictyol could alleviate the LPS-induced lung injury in mice by regulating the Nrf2 pathway and inhibiting the expression of inflammatory cytokines in macrophages, suggesting that eriodictyol could be used as a potential drug for the treatment of LPS-induced lung injury.

show abstract

Protective effect of florfenicol on acute lung injury induced by lipopolysaccharide in mice

Cited by 86 publications

References 25 publications

The effects of florfenicol on lymphocyte subsets and humoral immune response in mice

The effects of florfenicol on lymphocyte subsets and humoral immune response in mice

Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice

Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity

Contact Info

Product

Resources

About